HHS ClinicalTrials.Gov Rule Details Penalties For Failure To Submit
Executive Summary
The US department's final rule for disclosing summary results to clinical trials extends to early studies of unapproved products.
You may also be interested in...
Firms Must Submit The Good, Bad, And Ugly Trial Data On Devices Under Clinical Trials Rule
Device firms will have to submit a lot more clinical trials outcomes data to the ClinicalTrials.gov portal – including for products that have not been cleared, approved, or launched – based on a final rule recently issued by HHS. Even though sponsors can delay reporting two years, the rule expands the volume of reports that will find their way to the public-facing, clinical trials website, and the change could have downsides, attorneys say.
Clinical Trial Reporting Would Expand To Unapproved Drugs Under FDA, NIH Reg
Advocates may press for even more disclosures to better understand economics of clinical research.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.